Evidence map›Paper›PMID 27092491›Full record

ReviewInternational journal of molecular sciences2016

Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma.

Maximilian Seles, Georg C Hutterer, Tobias Kiesslich, Karl Pummer, Ioana Berindan-Neagoe, Samantha Perakis, Daniela Schwarzenbacher, Michael Stotz, Armin Gerger, Martin Pichler

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. A novel prognostic NScientific reports · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Maximilian SelesDepartment of Urology, Medical University of Graz, A-8036 Graz, Austria. maximilian.seles@medunigraz.at.
Georg C HuttererDepartment of Urology, Medical University of Graz, A-8036 Graz, Austria. georg.hutterer@medunigraz.at.
Tobias KiesslichDepartment of Internal Medicine I, Salzburger Landeskliniken (SALK), Paracelsus Medical University, A-5020 Salzburg, Austria. t.kiesslich@salk.at.
Karl PummerDepartment of Urology, Medical University of Graz, A-8036 Graz, Austria. karl.pummer@medunigraz.at.
Ioana Berindan-NeagoeDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. ioananeagoe29@gmail.com.
Samantha PerakisInstitute of Human Genetics, Medical University of Graz, A-8036 Graz, Austria. samantha.perakis@medunigraz.at.
Daniela SchwarzenbacherDivision of Oncology, Department of Internal Medicine, Medical University of Graz, A-8036 Graz, Austria. daniela.schwarzenbacher@medunigraz.at.
Michael StotzDivision of Oncology, Department of Internal Medicine, Medical University of Graz, A-8036 Graz, Austria. michael.stotz@medunigraz.at.
Armin GergerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, A-8036 Graz, Austria. armin.gerger@medunigraz.at.
Martin PichlerDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. martin.pichler@medunigraz.at.
Medical University of Graz · ATThe University of Texas MD Anderson Cancer Center · USParacelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) represents a deadly disease with rising mortality despite intensive therapeutic efforts. It comprises several subtypes in terms of distinct histopathological features and different clinical presentations. Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts in the genome which vary in expression levels and length and perform diverse functions. They are involved in the inititation, evolution and progression of primary cancer, as well as in the development and spread of metastases. Recently, several lncRNAs were described in RCC. This review emphasises the rising importance of lncRNAs in RCC. Moreover, it provides an outlook on their therapeutic potential in the future.

Indexed as

AnimalsCarcinoma, Renal CellGene Expression Regulation, NeoplasticHumansKidneyKidney NeoplasmsNeoplasm MetastasisRNA, Long NoncodingRNA, Long Noncodinglong non-coding RNAsmetastasesrenal cell cancer-carcinoma

Identifiers

PMID27092491
PMCPMC4849029
OpenAlexW2340796679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.